Scholarlink

<p>Colorectal cancer, a highly prevalent malignant tumor on a global scale, requires the development of novel therapeutic strategies that are both highly efficient and less toxic. This study presents a novel electro-responsive drug delivery system for colorectal cancer therapy. The synthesized composite exhibited distinct redox activity in 0.1&#xa0;M PBS (pH 7.0), with an enhanced oxidation peak current (0.65&#xa0;mA) compared to the drug-free matrix, indicating improved electron transfer upon loading compound 1. Fluorescence intensity significantly increased to ~ 290 a.u. (λ_em ≈ 575&#xa0;nm), verifying successful drug encapsulation. Electrochemical impedance spectroscopy further confirmed increased charge transfer resistance (Rct ≈ 5950 Ω), suggesting stable drug immobilization. Time-resolved fluorescence analysis revealed over 95% drug release within 320&#xa0;min in PBS (pH 6.0), while applied potential and pH modulated release efficiency, reaching &gt; 95% at 0.8&#xa0;V and pH 2.0, respectively. In vitro CCK-8 assays demonstrated that Glucose–MPTMS@CP1@1 significantly inhibited proliferation of HCT116 and SW480 cells in a time-dependent manner, with stronger effects observed in HCT116 (<i>P</i> &lt; 0.01). These results highlight Glucose–MPTMS@CP1@1 as a promising electrochemically controlled, pH-responsive platform for targeted colorectal cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Electrochemical Drug Delivery of Plant-Derived Therapeutics via a Silica–Polysaccharide Electrode for Colorectal Cancer Inhibition

  • 期刊论文

  • 发表日期：

    2025年7月17日

查看全文
  • Yanbin Chen,
  • Xiaodong Xu,
  • Xin Liu,
  • Xinye Hu

摘要

Colorectal cancer, a highly prevalent malignant tumor on a global scale, requires the development of novel therapeutic strategies that are both highly efficient and less toxic. This study presents a novel electro-responsive drug delivery system for colorectal cancer therapy. The synthesized composite exhibited distinct redox activity in 0.1 M PBS (pH 7.0), with an enhanced oxidation peak current (0.65 mA) compared to the drug-free matrix, indicating improved electron transfer upon loading compound 1. Fluorescence intensity significantly increased to ~ 290 a.u. (λ_em ≈ 575 nm), verifying successful drug encapsulation. Electrochemical impedance spectroscopy further confirmed increased charge transfer resistance (Rct ≈ 5950 Ω), suggesting stable drug immobilization. Time-resolved fluorescence analysis revealed over 95% drug release within 320 min in PBS (pH 6.0), while applied potential and pH modulated release efficiency, reaching > 95% at 0.8 V and pH 2.0, respectively. In vitro CCK-8 assays demonstrated that Glucose–MPTMS@CP1@1 significantly inhibited proliferation of HCT116 and SW480 cells in a time-dependent manner, with stronger effects observed in HCT116 (P < 0.01). These results highlight Glucose–MPTMS@CP1@1 as a promising electrochemically controlled, pH-responsive platform for targeted colorectal cancer therapy.